SIGY Sigyn Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1642159 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.3%
TTM EPS YoY39.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,144.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4,464.7%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-811.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $29,681 | $7,482 | $8,842 | $94,096 | $206,161 | $240,429 | $232,593 | $215,933 |
| SG&A expense | $306,796 | $412,023 | $487,041 | $495,744 | $564,683 | $324,868 | $359,541 | $613,746 |
| Operating income | -$386,529 | -$469,513 | -$546,059 | -$478,010 | -$808,458 | -$602,805 | -$629,972 | -$717,236 |
| Pretax income | -$578,503 | -$1.45M | -$668,564 | -$522,818 | -$1.20M | -$862,383 | -$758,088 | -$1.18M |
| Net income | -$578,503 | -$1.45M | -$668,564 | -$522,818 | -$1.20M | -$862,383 | -$758,088 | -$1.18M |
| EBITDA | -$386,529 | -$469,513 | -$544,696 | -$476,647 | -$807,095 | -$601,441 | -$628,449 | -$715,626 |
| EPS (basic) | -0.36 | -0.90 | -0.42 | — | -0.94 | -0.70 | -0.62 | — |
| EPS (diluted) | -0.36 | -0.90 | -0.42 | — | -0.94 | -0.70 | -0.62 | — |
| Weighted avg. shares (diluted) | 1.61M | 1.61M | 1.61M | — | 1.27M | 1.24M | 1.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $85,571 | $459 | $12,895 | $12,144 | $164,788 | $53,644 | $32,838 | $11,690 |
| Inventory | — | — | — | — | $50,000 | $50,000 | $50,000 | $50,000 |
| Current assets | $85,571 | $1,759 | $68,095 | $21,244 | $269,108 | $146,376 | $134,428 | $118,063 |
| PP&E, net | — | — | $8,322 | $9,685 | $11,048 | $12,411 | $13,773 | $15,296 |
| Total assets | $135,571 | $51,759 | $244,309 | $213,719 | $427,438 | $320,165 | $323,295 | $321,806 |
| Current liabilities | $3.99M | $5.49M | $5.15M | $4.61M | $4.28M | $3.90M | $4.23M | $3.61M |
| Short-term debt | $720,687 | $262,062 | $212,920 | $0 | — | — | — | — |
| Long-term debt | $3.55M | $2.49M | $2.40M | $2.02M | $2.00M | $2.01M | $2.78M | $2.51M |
| Total debt | $4.27M | $2.75M | $2.61M | $2.02M | $2.00M | $2.01M | $2.78M | $2.51M |
| Total liabilities | $6.05M | $5.49M | $5.19M | $4.67M | $4.35M | $3.99M | $4.34M | $3.73M |
| Shareholders' equity | -$5.92M | -$5.44M | -$4.95M | -$4.46M | -$3.92M | -$3.67M | -$4.02M | -$3.41M |
| Net debt | $4.18M | $2.75M | $2.60M | $2.01M | $1.83M | $1.96M | $2.75M | $2.50M |
| Shares outstanding | 1.61M | 1.61M | 1.61M | 1.61M | 1.42M | 1.26M | 1.22M | 1.29M |
| Cash flow statement | ||||||||
| Operating cash flow | -$199,326 | -$152,436 | -$294,446 | -$290,218 | -$163,812 | -$182,794 | -$235,612 | -$127,894 |
| Financing cash flow | $284,438 | $140,000 | $295,197 | $137,574 | $274,956 | $203,600 | $256,760 | $75,000 |
| Depreciation & amortization | $0 | $0 | $1,363 | $1,363 | $1,363 | $1,364 | $1,523 | $1,610 |
| Stock-based compensation | $50,000 | $50,000 | $50,000 | $37,500 | $37,500 | $37,500 | $37,500 | $103,058 |
Free plan shows the latest 8 periods; Pro shows all 44 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.